Sands Capital group (NASDAQ: IKT) discloses 9.3% Inhibikase stake plus large warrants

Rhea-AI Filing Summary

Sands Capital Life Sciences Pulse Fund II, L.P., together with related entities and Frank M. Sands, reports beneficial ownership of 13,018,965 shares of Inhibikase Therapeutics, Inc. common stock, representing 9.3% of the class based on 139,535,900 shares outstanding as of August 4, 2026. The shares are held with shared voting and dispositive power among the reporting persons.

The group also holds a Series A-1 warrant for 5,475,000 shares and a Series B-1 warrant for 10,068,120 shares, acquired under an October 9, 2024 securities purchase agreement. These warrants are not included in the reported ownership because they are not exercisable within 60 days and are subject to a 19.99% beneficial ownership limitation, which restricts exercises that would push ownership above that level. Each reporting person and the related general partners disclaim beneficial ownership beyond their pecuniary interest.

Key Figures

Shares beneficially owned: 13,018,965 shares Ownership percentage: 9.3% Shares outstanding: 139,535,900 shares +4 more

7 metrics

Shares beneficially owned 13,018,965 shares Common stock beneficially owned by the reporting persons

Ownership percentage 9.3% Portion of Inhibikase common stock class beneficially owned

Shares outstanding 139,535,900 shares Shares outstanding as of August 4, 2026, used for percentage calculation

Series A-1 Warrant size 5,475,000 shares Shares of common stock underlying the Series A-1 Warrant

Series B-1 Warrant size 10,068,120 shares Shares of common stock underlying the Series B-1 Warrant

Beneficial ownership cap 19.99% Maximum ownership allowed immediately after warrant exercise

Issuer par value $0.001 per share Par value of Inhibikase common stock

Key Terms

beneficial ownership, Series A-1 warrant, Series B-1 warrant, beneficial ownership limitation, +2 more

6 terms

beneficial ownership financial

"The Reporting Persons each disclaim beneficial ownership of any securities beyond its pecuniary interest"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Series A-1 warrant financial

"does not include a Series A-1 warrant to purchase 5,475,000 shares of Common Stock"

Series B-1 warrant financial

"or a Series B-1 warrant to purchase 10,068,120 shares of Common Stock"

beneficial ownership limitation financial

"will not have the right to exercise any portion of such warrant if such holder... would beneficially own in excess of 19.99%"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

Warrant Initial Registration Statement regulatory

"the initial filing date of the registration statement covering the resale of the shares of Common Stock underlying the Series A-1 warrants and Series B-1 warrants"

Initial Exercise Date financial

"The Series B-1 Warrant is exercisable on the Initial Exercise Date"

FAQ

What percentage of Inhibikase Therapeutics (IKT) does Sands Capital report owning?

Sands Capital-related entities report beneficial ownership of 13,018,965 shares of Inhibikase Therapeutics, equal to 9.3% of the outstanding common stock, using a base of 139,535,900 shares outstanding as of August 4, 2026.

How many Inhibikase (IKT) shares are beneficially owned by Sands Capital’s fund?

Sands Capital Life Sciences Pulse Fund II, L.P. and related parties beneficially own 13,018,965 shares of Inhibikase common stock, with shared voting and dispositive power over all of these shares among the reporting persons.

What additional Inhibikase (IKT) warrants does Sands Capital hold?

The reporting group holds a Series A-1 warrant for 5,475,000 shares and a Series B-1 warrant for 10,068,120 shares of Inhibikase common stock, acquired under an October 9, 2024 securities purchase agreement with the company.

Are Sands Capital’s Inhibikase (IKT) warrants included in the 9.3% ownership figure?

No. The Series A-1 and Series B-1 warrants are excluded from the 9.3% ownership because they are not exercisable within 60 days of the report date and therefore are not counted as beneficially owned shares.

What ownership cap applies to Sands Capital’s Inhibikase (IKT) warrants?

Both warrants include a 19.99% beneficial ownership limitation. The holder cannot exercise any portion of a warrant if, together with its affiliates, it would beneficially own more than 19.99% of the outstanding common stock immediately after exercise.

Who are the reporting persons related to Sands Capital in this Inhibikase (IKT) stake?

The reporting persons are Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC, and Frank M. Sands, along with related general partners. They each disclaim beneficial ownership beyond their pecuniary interest in the securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 11:49 AM Accepted by SEC EDGAR 08/13/2026 - 11:49 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Inhibikase Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

45719W205

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45719W205

1

Names of Reporting Persons

Sands Capital Life Sciences Pulse Fund II, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 13,018,965.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 13,018,965.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,018,965.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.3 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 139,535,900 Shares outstanding as of August 4, 2026 (according to the Issuer's most recent 10-Q as filed with the Securities and Exchange Commission on August 11, 2026).

SCHEDULE 13G

CUSIP Number(s): 45719W205

1

Names of Reporting Persons

Sands Capital Alternatives, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 13,018,965.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 13,018,965.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,018,965.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.3 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 139,535,900 Shares outstanding as of August 4, 2026 (according to the Issuer's most recent 10-Q as filed with the Securities and Exchange Commission on August 11, 2026).

SCHEDULE 13G

CUSIP Number(s): 45719W205

1

Names of Reporting Persons

SANDS FRANK M.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 13,018,965.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 13,018,965.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,018,965.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.3 %

12

Type of Reporting Person (See Instructions)

IN, HC

Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 139,535,900 Shares outstanding as of August 4, 2026 (according to the Issuer's most recent 10-Q as filed with the Securities and Exchange Commission on August 11, 2026).

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Inhibikase Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1000 N. WEST STREET, SUITE 1200, 1000 N. WEST STREET, SUITE 1200, WILMINGTON, DELAWARE, 19801.
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed jointly by: (i) Sands Capital Life Sciences Pulse Fund II, L.P. ("Sands Pulse Fund II"), with respect to the shares of Common Stock held by it; (ii) Sands Capital Alternatives, LLC ("Sands Capital Alternatives"), the investment manager of Sands Pulse Fund II, with respect to the shares of Common Stock held by Sands Pulse Fund II; and (iii) Frank M. Sands ("Sands"), with respect to the shares of Common Stock held by Sands Pulse Fund II. Sands Pulse Fund II, Sands Capital Alternatives and Sands are together referred to herein as the "Reporting Persons". Sands Capital Life Sciences Pulse Fund II-GP, L.P. ("Sands Pulse GP LP") is the general partner of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund-GP, LLC ("Sands Pulse GP LLC" and, together with Sands Pulse GP LP, the "Sands General Partners") is the general partner of Sands Pulse GP LP. Sands Capital Alternatives is the investment manager of Sands Pulse Fund II and thus may be deemed to beneficially own the shares of Common Stock held by Sands Pulse Fund II. Sands holds ultimate voting and investment power over securities held by Sands Pulse Fund II, and thus may be deemed to beneficially own the shares of Common Stock held by Sands Pulse Fund II. Each Reporting Person and the Sands General Partners disclaim beneficial ownership of any securities beyond its pecuniary interest therein.
(b)	Address or principal business office or, if none, residence: The principal business address of each of the Reporting Persons and the Sands General Partners is 1000 Wilson Blvd., Suite 3000, Arlington, VA 22209.
(c)	Citizenship: Sands Pulse Fund II and Sands Pulse GP LP are organized under the laws of the Cayman Islands. Sands Capital Alternatives and Sands Pulse GP LLC are organized under the laws of Delaware. Sands is a citizen of the United States.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 45719W205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See rows 5 through 11 of the cover pages. The ownership disclosed in rows 5 through 11 of the cover pages does not include a Series A-1 warrant to purchase 5,475,000 shares of Common Stock (the "Series A-1 Warrant") or a Series B-1 warrant to purchase 10,068,120 shares of Common Stock (the "Series B-1 Warrant"), in each case held by Sands Pulse Fund II, each of which was purchased by Sands Pulse Fund II from the Issuer pursuant to that certain securities purchase agreement dated October 9, 2024 between the Issuer and, among certain other institutional and accredited investors, Sands Pulse Fund II (the "Purchase Agreement"). The Series A-1 Warrant is exercisable on the earlier of (a) the 75th calendar day following the initial filing date of the registration statement covering the resale of the shares of Common Stock underlying the Series A-1 warrants and Series B-1 warrants issued pursuant to the Purchase Agreement (the "Warrant Initial Registration Statement") if the Securities and Exchange Commission ("SEC") notifies the Issuer that it will "review" the Warrant Initial Registration Statement and (b) the fifth business day after the date the Issuer is notified (orally or in writing, whichever is earlier) by the SEC that the Warrant Initial Registration Statement will not be "reviewed" or (even if previously subject to review pursuant to clause (a) of this sentence) will not be subject to further review (the "Initial Exercise Date"). The Series B-1 Warrant is exercisable on the Initial Exercise Date, provided that, to the extent exercisable, the Series A-1 Warrant issued to Sands Pulse Fund II has been exercised in full either by Sands Pulse Fund II or its transferee permitted by the terms of the Series A-1 Warrant. The Series A-1 Warrant and the Series B-1 Warrant each provide that the holder of such warrant will not have the right to exercise any portion of such warrant if such holder, together with its affiliates, would beneficially own in excess of 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Reporting Persons each disclaim beneficial ownership of the shares of Common Stock underlying each of the Series A-1 Warrant and Series B-1 Warrant because neither the Series A-1 Warrant nor the Series B-1 Warrant is exercisable within 60 days of this filing and such date is not determinable at this time.
(b)	Percent of class: See rows 5 through 11 of the cover pages.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See rows 5 through 11 of the cover pages.
	(ii) Shared power to vote or to direct the vote: See rows 5 through 11 of the cover pages.
	(iii) Sole power to dispose or to direct the disposition of: See rows 5 through 11 of the cover pages.
	(iv) Shared power to dispose or to direct the disposition of: See rows 5 through 11 of the cover pages.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sands Capital Life Sciences Pulse Fund II, L.P.

Signature:	/s/ Jonathan Goodman
Name/Title:	Jonathan Goodman, General Counsel of the GP of the GP of Sands Capital Life Sciences Pulse Fund II, L.P.
Date:	08/13/2026

Sands Capital Alternatives, LLC

Signature:	/s/ Jonathan Goodman
Name/Title:	Jonathan Goodman, General Counsel
Date:	08/13/2026

SANDS FRANK M.

Signature:	/s/ Frank M. Sands
Name/Title:	Frank M. Sands
Date:	08/13/2026

Comments accompanying signature: Sands Capital Life Sciences Pulse Fund II, L.P. signed by Sands Capital Life Sciences Pulse Fund II-GP, L.P., its general partner, by Sands Capital Life Sciences Pulse Fund II-GP, LLC, its general partner, by Jonathan Goodman, General Counsel.